This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020; 382: 427-436

Published: 20th March 2020

Authors: Choi IJ, Kim CG, Lee JY, Kim Y-I, Kook M-C, Park B et al.

Conclusion

Some 3100 first-degree relatives were screened; 1838 had H. pylori infection and were randomly allocated to eradication therapy. After a median of nine years, people who have eradication therapy were less likely to develop stomach cancer: hazard ratio 0.45, 95 per cent c.i. 0.21 to 0.94, P=0.03. Cancer was more likely if H. pylori was not eradicated.

Pubmed Link

You may also be interested in

Scientific Surgery

Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemo-radiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. A randomized clinical trial. JAMA Surg 2021; 156: 444-451.

Authors: Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y et al.

Scientific Surgery

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-1203.

Authors: Kelly RJ, Ajani JA, Kuzdzal J, Zander T, van Cutsem E, Piessen G et al.

Scientific Surgery

Surgical morbidity and mortality from the multicenter randomized controlled NeoRes II Trial. Standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2020; 272: 684-689.

Authors: Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I et al.

Scientific Surgery

Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer. A randomized clinical trial. JAMA Surg 2019; 154: 1093-1101

Authors: Li Z, Shan F, Ying X, Zhang Y, E J-Y, Wang Y et al.

Scientific Surgery

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.

Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.

Scientific Surgery

Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.

Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.

Scientific Surgery

Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.

Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.

Scientific Surgery

Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.

Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.

Scientific Surgery

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.

Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.

Scientific Surgery

Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.

Authors: Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al. et al.

Scientific Surgery

Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.

Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.

Scientific Surgery

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.

Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.